Evidence map›Paper›PMID 33777047›Full record

ArticleFrontiers in immunology

Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody.

Simon Gebremeskel, Julia Schanin, Krysta M Coyle, Melina Butuci, Thuy Luu, Emily C Brock, Alan Xu, Alan Wong, John Leung, Wouter Korver and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations.Pathophysiology : the official journal of the International Society for Pathophysiology · 2024
    Review
  18. Article
  19. Review
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Simon GebremeskelAllakos Inc., Redwood City, CA, United States.
Julia SchaninAllakos Inc., Redwood City, CA, United States.
Krysta M CoyleDepartment of Molecular Biology and Biochemistry, Research Centre, Simon Fraser University, Vancouver, BC, Canada.
Melina ButuciAllakos Inc., Redwood City, CA, United States.
Thuy LuuAllakos Inc., Redwood City, CA, United States.
Emily C BrockAllakos Inc., Redwood City, CA, United States.
Alan XuAllakos Inc., Redwood City, CA, United States.
Alan WongAllakos Inc., Redwood City, CA, United States.
John LeungAllakos Inc., Redwood City, CA, United States.
Wouter KorverAllakos Inc., Redwood City, CA, United States.
Ryan D MorinDepartment of Molecular Biology and Biochemistry, Research Centre, Simon Fraser University, Vancouver, BC, Canada.
Robert P SchleimerDivision of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Bruce S BochnerDivision of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Bradford A YoungbloodAllakos Inc., Redwood City, CA, United States.
Allakos (United States) · USNorthwestern University · USSimon Fraser University · CA

Funding

Population-based CRS epidemiology: sex differences, natural history, and long-term outcomes based on clinically-defined phenotypes and biologically-based endotypes - GeisingerP01AI145818 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SCHLEIMER, ROBERT P · 2019 to 2023
$9.3M
NIAID NIH HHS P01 AI145818
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection represents a global health crisis. Immune cell activation via pattern recognition receptors has been implicated as a driver of the hyperinflammatory response seen in COVID-19. However, our understanding of the specific immune responses to SARS-CoV-2 remains limited. Mast cells (MCs) and eosinophils are innate immune cells that play pathogenic roles in many inflammatory responses. Here we report MC-derived proteases and eosinophil-associated mediators are elevated in COVID-19 patient sera and lung tissues. Stimulation of viral-sensing toll-like receptors

Indexed as

AnimalsAntibodies, MonoclonalAntigens, CDAntigens, Differentiation, B-LymphocyteCase-Control StudiesCOVID-19CytokinesDisease Models, AnimalEosinophilsHost-Pathogen InteractionsHumansLectinsMast CellsMice, TransgenicPeptide HydrolasesRespiratory Syncytial VirusesAntibodies, MonoclonalAntigens, CDAntigens, Differentiation, B-LymphocyteCytokinesLectinsPeptide HydrolasesSIGLEC8 protein, humanToll-Like ReceptorsCOVID-19eosinophillirentelimabmast cellSARS-CoV-2Siglec-8Toll-like receptorviral inflammation

Identifiers

PMID33777047
PMCPMC7988091
OpenAlexW3134128337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.